Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $137 to $149.
Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $149
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.